Obesity Medicine

Your daily dose of clinical news you may have missed.

Findings highlight the need to develop strategies to improve weight management in primary care, according to study authors.

Efficacy of the daily pill met the standard now established by the once-weekly injection of 15% loss of baseline bodyweight in adults with overweight or obesity, says Novo Nordisk.

A nationally recognized obesity expert discusses mental health in women with obesity.

Your daily dose of clinical news you may have missed.

Dr Caroline Apovian reminds primary care clinicians who care for patients with obesity that diet and lifestyle counseling are essential for maximum results.

Participants with overweight or obesity had lower testicular volume than their healthy peers, putting them at risk for infertility later in adulthood.

The dual GIP/GLP-1 receptor agonist was associated with a nearly 15% reduction in body weight in adults with overweight/obesity and without type 2 diabetes.

GLP-1 RA side effects such as nausea and vomiting can be minimized by starting at the lowest available dose and titrating slowly; Dr Caroline Apovian explains why.

GLP-1 receptor agonist-based medications for obesity modify gut hormone imbalances, making diet and lifestyle change far more effective, explains Caroline Apovian, MD.

The American College of Physicians announced an initiative that renews and expands its focus on equitable access to obesity care, including new resources for physicians.

Your daily dose of clinical news you may have missed.

Dubbed the "twincretin," the GLP-1/GIP RA met weight and HgbA1c reduction endpoints, with nearly half of tirzepatide-treated patients achieving weight loss of at least 15%.

For persons diagnosed with obesity, a prescription antiobesity medication is just one part of optimal care that includes significant lifestyle change as well, says Caroline Apovian, MD.

Apovian: GLP-1 receptor agonists are the first antiobesity medications to simulate human physiology, which is why they sustain weight loss and are meant for long-term use.

In persons with biopsy-confirmed NASH, the probability of disease resolution was more than 3X greater after RGB or SG vs lifestyle intervention at 52 weeks.

Caroline Apovian, MD, highlights how drugs like semaglutide 2.4 mg treat the chronic relapsing disease of obesity and why a distinction from "weight-loss drugs" is critical.

A family physician and obesity medicine physician talks about chronic pain in patients with obesity.

Your daily dose of clinical news you may have missed.

Researchers found sex-specific brain signals that appear to confirm that different drivers lead men and women to develop obesity.

A new study examines the legacy effects of weight loss on cardiometabolic disease risk factors, finding benefits persist up to 5 years, despite weight regain.

From highest percentage of adults with obesity to lowest percentage of adults with hypertension, see how obesity hits home in our new slideshow.

Authors of new study say results underscore need for effective strategies to optimize metabolic status and prevent obesity-related complications among persons with obesity.

Your daily dose of clinical news you may have missed.

Youth at the upper range of normal weight had a 26% higher risk of developing hypertension than those in the lower range of normal weight, according to a new study.

ACC2023. Risk for MACE was nearly 7-fold higher in participants on a keto diet whose LDL-C was already high compared with those on a standard diet with LDL-C in a normal range.

ACC 2023. Results from a 2-decade study showed that all-cause mortality rates were significantly higher in patients with obesity with uncontrolled HTN compared to those without HTN.

Three tips on how to support patients on their weight management journey this year.

Your daily dose of clinical news you may have missed.

The proportion of adults with diabetes and obesity in the US increased from 1999 to 2020, though more adults achieved blood pressure and lipid control during the same period.